![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ANKRD11 |
Gene summary for ANKRD11 |
![]() |
Gene information | Species | Human | Gene symbol | ANKRD11 | Gene ID | 29123 |
Gene name | ankyrin repeat domain 11 | |
Gene Alias | ANCO-1 | |
Cytomap | 16q24.3 | |
Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | Q6UB99 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
29123 | ANKRD11 | C46 | Human | Oral cavity | OSCC | 9.64e-11 | 5.73e-01 | 0.1673 |
29123 | ANKRD11 | C51 | Human | Oral cavity | OSCC | 1.86e-13 | 1.24e+00 | 0.2674 |
29123 | ANKRD11 | C57 | Human | Oral cavity | OSCC | 1.66e-03 | 4.58e-01 | 0.1679 |
29123 | ANKRD11 | C06 | Human | Oral cavity | OSCC | 2.54e-11 | 1.74e+00 | 0.2699 |
29123 | ANKRD11 | C08 | Human | Oral cavity | OSCC | 7.00e-14 | 5.74e-01 | 0.1919 |
29123 | ANKRD11 | C09 | Human | Oral cavity | OSCC | 6.25e-07 | 6.13e-01 | 0.1431 |
29123 | ANKRD11 | LN22 | Human | Oral cavity | OSCC | 7.48e-07 | 1.34e+00 | 0.1733 |
29123 | ANKRD11 | LN46 | Human | Oral cavity | OSCC | 3.30e-02 | 4.31e-01 | 0.1666 |
29123 | ANKRD11 | LP15 | Human | Oral cavity | LP | 2.32e-04 | 1.19e+00 | 0.2174 |
29123 | ANKRD11 | EOLP-1 | Human | Oral cavity | EOLP | 6.14e-22 | 7.98e-01 | -0.0202 |
29123 | ANKRD11 | NEOLP-1 | Human | Oral cavity | NEOLP | 2.28e-08 | 4.93e-01 | -0.0194 |
29123 | ANKRD11 | NEOLP-2 | Human | Oral cavity | NEOLP | 2.61e-06 | 4.05e-01 | -0.0196 |
29123 | ANKRD11 | NEOLP-3 | Human | Oral cavity | NEOLP | 9.39e-12 | 4.68e-01 | -0.0191 |
29123 | ANKRD11 | SYSMH1 | Human | Oral cavity | OSCC | 5.66e-20 | 7.19e-01 | 0.1127 |
29123 | ANKRD11 | SYSMH2 | Human | Oral cavity | OSCC | 7.28e-24 | 1.00e+00 | 0.2326 |
29123 | ANKRD11 | SYSMH3 | Human | Oral cavity | OSCC | 1.42e-50 | 1.25e+00 | 0.2442 |
29123 | ANKRD11 | SYSMH5 | Human | Oral cavity | OSCC | 4.16e-16 | 6.21e-01 | 0.0647 |
29123 | ANKRD11 | SYSMH6 | Human | Oral cavity | OSCC | 1.75e-04 | 3.19e-01 | 0.1275 |
29123 | ANKRD11 | HTA12-15-2 | Human | Pancreas | PDAC | 1.32e-03 | 5.65e-01 | 0.2315 |
29123 | ANKRD11 | HTA12-23-1 | Human | Pancreas | PDAC | 9.06e-06 | 8.01e-01 | 0.3405 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0048705 | Colorectum | CRC | skeletal system morphogenesis | 37/2078 | 220/18723 | 6.58e-03 | 4.71e-02 | 37 |
GO:00603242 | Esophagus | ESCC | face development | 34/8552 | 44/18723 | 1.90e-05 | 1.67e-04 | 34 |
GO:00101711 | Esophagus | ESCC | body morphogenesis | 30/8552 | 43/18723 | 1.21e-03 | 5.88e-03 | 30 |
GO:00603253 | Esophagus | ESCC | face morphogenesis | 21/8552 | 28/18723 | 1.57e-03 | 7.33e-03 | 21 |
GO:00487052 | Esophagus | ESCC | skeletal system morphogenesis | 120/8552 | 220/18723 | 4.90e-03 | 1.89e-02 | 120 |
GO:00603232 | Esophagus | ESCC | head morphogenesis | 22/8552 | 32/18723 | 7.12e-03 | 2.58e-02 | 22 |
GO:0060325 | Liver | NAFLD | face morphogenesis | 8/1882 | 28/18723 | 5.07e-03 | 3.96e-02 | 8 |
GO:0060324 | Oral cavity | OSCC | face development | 28/7305 | 44/18723 | 8.15e-04 | 4.35e-03 | 28 |
GO:00603252 | Oral cavity | OSCC | face morphogenesis | 18/7305 | 28/18723 | 5.96e-03 | 2.27e-02 | 18 |
GO:0060323 | Oral cavity | OSCC | head morphogenesis | 19/7305 | 32/18723 | 1.56e-02 | 5.00e-02 | 19 |
GO:00603241 | Oral cavity | NEOLP | face development | 16/2005 | 44/18723 | 6.27e-06 | 1.26e-04 | 16 |
GO:00603231 | Oral cavity | NEOLP | head morphogenesis | 12/2005 | 32/18723 | 6.38e-05 | 8.40e-04 | 12 |
GO:00603251 | Oral cavity | NEOLP | face morphogenesis | 11/2005 | 28/18723 | 7.84e-05 | 1.00e-03 | 11 |
GO:0010171 | Oral cavity | NEOLP | body morphogenesis | 14/2005 | 43/18723 | 9.66e-05 | 1.18e-03 | 14 |
GO:00487051 | Oral cavity | NEOLP | skeletal system morphogenesis | 36/2005 | 220/18723 | 6.47e-03 | 3.33e-02 | 36 |
GO:00603254 | Skin | AK | face morphogenesis | 10/1910 | 28/18723 | 2.78e-04 | 2.94e-03 | 10 |
GO:00101712 | Skin | AK | body morphogenesis | 12/1910 | 43/18723 | 9.25e-04 | 7.53e-03 | 12 |
GO:00603233 | Skin | AK | head morphogenesis | 10/1910 | 32/18723 | 9.35e-04 | 7.56e-03 | 10 |
GO:00603243 | Skin | AK | face development | 12/1910 | 44/18723 | 1.16e-03 | 8.88e-03 | 12 |
GO:00603244 | Thyroid | PTC | face development | 24/5968 | 44/18723 | 1.52e-03 | 8.49e-03 | 24 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ANKRD11 | SNV | Missense_Mutation | c.4129N>T | p.Gly1377Cys | p.G1377C | Q6UB99 | protein_coding | deleterious(0.01) | benign(0.43) | TCGA-A2-A04P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | PD | |
ANKRD11 | SNV | Missense_Mutation | c.3844N>A | p.Glu1282Lys | p.E1282K | Q6UB99 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.906) | TCGA-A2-A0SX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | PD | |
ANKRD11 | SNV | Missense_Mutation | c.907G>A | p.Glu303Lys | p.E303K | Q6UB99 | protein_coding | deleterious(0) | probably_damaging(0.965) | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
ANKRD11 | SNV | Missense_Mutation | novel | c.1042N>A | p.Glu348Lys | p.E348K | Q6UB99 | protein_coding | deleterious(0.01) | probably_damaging(0.965) | TCGA-A7-A5ZW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
ANKRD11 | SNV | Missense_Mutation | c.5149N>A | p.Glu1717Lys | p.E1717K | Q6UB99 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
ANKRD11 | SNV | Missense_Mutation | c.4737N>A | p.Met1579Ile | p.M1579I | Q6UB99 | protein_coding | deleterious(0) | benign(0.041) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
ANKRD11 | SNV | Missense_Mutation | c.461N>T | p.Ala154Val | p.A154V | Q6UB99 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
ANKRD11 | SNV | Missense_Mutation | c.1571N>T | p.Ser524Leu | p.S524L | Q6UB99 | protein_coding | deleterious(0.01) | probably_damaging(0.945) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ANKRD11 | SNV | Missense_Mutation | c.2150N>T | p.Ser717Leu | p.S717L | Q6UB99 | protein_coding | tolerated(0.06) | benign(0.035) | TCGA-AO-A1KS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
ANKRD11 | SNV | Missense_Mutation | c.3172N>C | p.Glu1058Gln | p.E1058Q | Q6UB99 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.69) | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |